Canakinumab for untreated Schnitzler syndrome [ID4063]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria TS ID 10250Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 TS ID 10766Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome TS ID 11820Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over TS ID 11891Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable ID 6272Status:Topic selectionProgramme:Health technology evaluationExpected publication date: TBC
Helge for detecting haemolysisStatus:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC
Spectra Optia for plasma exchange, (MT828)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC